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Electronic health recordReference intervals are critical for the interpretation of laboratory results. The development of reference
intervals using traditional methods is time consuming and costly. An alternative approach, known as an a
posteriori method, requires an expert to enumerate diagnoses and procedures that can affect the mea-
surement of interest. We develop a method, LIMIT, to use laboratory test results from a clinical database
to identify ICD9 codes that are associated with extreme laboratory results, thus automating the a
posteriorimethod. LIMIT was developed using sodium serum levels, and validated using potassium serum
levels, both tests for which harmonized reference intervals already exist. To test LIMIT, reference
intervals for total hemoglobin in whole blood were learned, and were compared with the hemoglobin ref-
erence intervals found using an existing a posteriori approach. In addition, prescription of iron supple-
ments were used to identify individuals whose hemoglobin levels were low enough for a clinician to
choose to take action. This prescription data indicating clinical action was then used to estimate the
validity of the hemoglobin reference interval sets. Results show that LIMIT produces usable reference
intervals for sodium, potassium and hemoglobin laboratory tests. The hemoglobin intervals produced
using the data driven approaches consistently had higher positive predictive value and specificity in pre-
dicting an iron supplement prescription than the existing intervals. LIMIT represents a fast and inexpen-
sive solution for calculating reference intervals, and shows that it is possible to use laboratory results and
coded diagnoses to learn laboratory test reference intervals from clinical data warehouses.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Reference intervals are a critical part of the interpretation of
laboratory results, and have been described as the most widely
used medical decision-making tool [1]. Ideally, a patient specific
approach would be taken for the interpretation of laboratory
results, because historic data from the patient of interest is the best
indicator of the normality of the current results [2]. Such a person-
alized approach would allow small fluctuations to be identified, a
desirable characteristic given recent studies showing the predic-
tive power of gradual temporal trends [3,4]. However, large
amounts of patient specific data are rarely available. For this rea-
son, population based reference intervals are the norm, and their
use for result interpretation is ubiquitous in laboratories today [2].
The concept of reference intervals was first widely adopted in
1969 [5], and today reference intervals are required for all labora-
tory developed tests [6]. Aytekin and Emerk provide three reasonsthat the description and definition of reference intervals is not a
solved problem [7]. First, as new biomarkers are identified and
adopted in clinical practice, it is important that the associated ref-
erence intervals are defined. For example, when identifying new
protein biomarkers, reference intervals for specific populations
can quantify the effect of age, sex, ethnicity or race on protein con-
centration, ensuring that these effects are considered in interpret-
ing the study results [8]. Second, a large number of reference
intervals that are currently in use were established for a Caucasian
population, and thus are not always suitable for use in interpreta-
tion of laboratory results of patients from different ethnic groups.
Separate reference intervals should be established for different
races and ethnicities. Third, many of the reference intervals that
are in use today were developed many years ago, and are specific
to measurement techniques and instruments that are no longer
in use. These reference intervals should be updated, or validated
for today’s measurement techniques and instrumentation.
Determining reference intervals requires a group of clinically
normal individuals in order to obtain a large number of normal
results for the test of interest [9]. This process is costly,
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mine patient ‘normality’ vary widely. Particularly rigorous criteria
may lead to only a fraction of healthy people being accepted into
the test group [2]. Therefore, the initial pool of possible subjects
must be large, increasing the cost of the process. A group of at least
120 reference individuals is typically recommended to establish
reference intervals [14]. It is recommended that all laboratories
develop their own reference intervals [2,12], to ensure that result-
ing intervals are appropriate for the population being served
[10,12,13,15].
For most clinics, the development of their own reference inter-
vals is a ‘practical impossibility’ [13], and reference intervals are
regularly adopted from the literature or other sources [11,12].
Reference intervals from manufacturers’ guidelines or published
literature may be used for FDA approved test sets, or in situations
where the specimens are difficult to obtain [9]. When a population
based reference interval is adopted, the population used for the
development of reference intervals should be as close as possible
to the patient group being served, with the exception of the disease
being tested for [15]. The International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC) has published guideli-
nes for the establishment and use of laboratory reference intervals
[14,16].
When not establishing a new reference interval and instead
adopting an already established reference interval, the IFCC recom-
mends that each laboratory verify the appropriateness of the refer-
ence intervals for their population [17]. This verification is required
by law for FDA approved or cleared devices [6], and it is recom-
mended that a group of at least 20 reference individuals are
included [14]. The verification process is more affordable than
establishing reference intervals, since the size of the reference
group required is much smaller, however the cost involved is still
a disincentive for laboratories. Healthy laboratory staff are often
used in the verification process. Reference intervals based on tests
from laboratory staff give a biased result that is not representative
of the patient population. Ideally, a patient’s comorbidities and
characteristics should be mirrored in the reference population
[18,19]. For example, results from hospitalized patients should
not be interpreted using reference intervals developed from
healthy ambulatory populations [2], and patient traits such as
BMI and nutritional habits (e.g. vegetarian diet) should match the
reference population [13]. Such subdivision of the population
based on patient characteristics will decrease the inter-individual
variability, and tighten the reference intervals [13]. Creating refer-
ence intervals based on such subdivision was found to decrease the
number of patients who had unexplained thrombocytopenia [20],
showing the importance and impact of such personalization. It
would be helpful to have reference intervals would require a scal-
able method, which is not currently available.
The use of laboratory data to develop reference intervals is gen-
erally via an indirect approach, in which the reference population
is chosen based on some statistical criteria [10–12,15,21]. For
example, a basic method may classify any results more than two
standard deviations from the mean as outliers, while a more
complex method may model the results as a sum of two Gaussian
distributions: one from the outlier results, and one from the
non-outlier results [11]. These indirect approaches are often used
to calculate reference intervals for pediatric and geriatric popula-
tions, where data is sparse [22,23]. The IFCC recommends that
the characteristics of the reference population are clearly defined
[13], which is not achievable using these purely statistical
approaches. Therefore, the IFCC does not recommend such indirect
approaches.
With the increasing availability of clinical data, the reference
population can be defined based on review of the electronic med-
ical records in an a posteriori approach [13], which meets the IFCCrecommendations but is still costly and time consuming due to the
time required from experts. For each test of interest, an expert
must define the diagnoses and procedures associated with abnor-
mal results. Patients with the corresponding ICD9 and CPT codes
must then be excluded from the cohort before the reference inter-
vals are calculated. This a posteriori process has been shown to give
accurate results [2,12,21], and is currently the most commonly
used system for defining reference intervals from data, with the
Australasian Association of Biochemists (AACB) suggesting the pos-
sible use of this method at an individual laboratory level [24].
However, this approach does not overcome the problem of scala-
bility, as exclusion rules must be developed manually for each test
and patient population of interest.
There have been attempts to automatically identify and remove
diseased patients from the data. Grossi et al. [25] work under the
assumption that repeated tests correspond to a higher probability
of disease, and select patients that have only one measurement for
the laboratory test of interest. Kouri et al. [2] exclude all but the
first measurement for each patient in order to avoid a potential
bias from repeated measurements. Both of these methods drasti-
cally decrease the size of the patient population making it difficult
to maintain statistical power and to draw valid conclusions. Weber
and Kohane [26] investigate laboratory test repeat interval as a
way to assess normality of a test result. They found that the repeat
interval between tests was shorter when the initial test was abnor-
mal, and were able to use this to determine which test results
physicians consider to be normal. While this method has good
results, the results being excluded are not directly tied to patient
characteristics, meaning that the characteristics of the remaining
patient population are not defined, and this process is not in line
with IFCC recommendations.
We propose that it is possible to use laboratory results and
coded diagnoses to learn laboratory test reference intervals. We
present an automated method to learn the ICD9 codes that are sig-
nificantly associated with extreme laboratory results using existing
clinical data. Doing so removes the key bottleneck—the need for
expert definition of exclusion criteria—of the a posteriori method,
while still meeting the IFCC recommendations. The crux of our
method is an unsupervised mechanism to identify the ICD9 codes
associated with extreme laboratory results (Fig. 1). Patients with
these codes are then removed from the reference population in
an iterative manner. The automated nature of this process means
that reference intervals can be inexpensively calculated for many
different patient populations, and that these calculations can be
repeated regularly to ensure accuracy. The ability to quickly and
inexpensively find reference intervals using different sets of results
will help to address the problem of biases in laboratory test data.
At its core, our method builds on the observation that a significant
proportion of specimens that are sent for laboratory testing are
normal [11]. This method is named LIMIT – Laboratory Information
Mining for Individualized Thresholds.2. Material and methods
LIMIT consists of 7 steps, from data extraction to comparison of
the resulting reference intervals, as shown in Fig. 1. Laboratory
results, ICD9 codes and patient demographics are extracted from
STRIDE (step 1), and the patients are split into two groups based
on Hampel outlier detection of their laboratory results: those with
no outlier results, and those with at least one outlier result (step 2).
Fisher’s Exact Test is then used to find ICD9 codes that are overrep-
resented in the outlier group (step 3). The ICD9 code that has the
lowest p-value is identified, and if the p-value is below a chosen
cutoff, this code is considered to be associated with extreme labo-
ratory levels (step 4). All patients with any mention of this ICD9
Fig. 1. Graphical representation of LIMIT method.
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and 5 are repeated until the lowest p-value found in step 3 is not
below the cutoff defined in step 4. The remaining population is
then used to find the reference interval by taking the percentiles
defining the central 95% of the results (step 6). The resulting refer-
ence intervals are compared to known intervals, or to intervals
found using an alternative method, such as the a posteriorimethod,
for validation (step 7). These steps are described in more detail in
the following sections.
2.1. Step 1: Data extraction
The Stanford Translational Research Integrated Database
Environment (STRIDE) was the primary source of data used for this
project [27]. STRIDE contains data from2million pediatric and adult
patients, and includes 25 million clinical encounters, 48 million
ICD9-coded inpatient and outpatient diagnoses, 157million labora-
tory test numeric results, and 16 million pharmacy orders. All labo-
ratory test data for the test of interest was extracted from STRIDE,
along with age and demographic information for all patients, and
all ICD9 codes attributed to each patient. The relative date (provided
as a time offset from the beginning of the record) of all laboratory
tests and ICD9 codes was part of this data set. A filtering step was
applied to exclude from the analysis all patients with no ICD9 diag-
noses attributed to them. The datamay be partitioned before use, by
stratifying on age, gender, ethnicity, or other relevant criteria that
may affect the analyte being tested, for example BMI or nutritional
habits such as vegetarianism. The partitioning criteria are specific to
the laboratory test of interest. Such partitioning aims to reduce the
variability between patients in each group, thus improving the util-
ity of the resulting reference intervals [10]. Analysis is performed on
each group separately, resulting in sets of reference intervals speci-
fic to the defined populations.
2.2. Step 2: Outlier detection
The Hampel method is used to identify extreme laboratory
results [28]. This method is recommended as a robust statistic by
the Clinical and Laboratory Standards Institute [29]. This outlier
detection method uses median and median absolute deviation
(MAD), making it a robust method that is not skewed when
outliers are present, a problem that the more common mean and
standard deviation based outlier detection methods suffer from
[30]. Outliers are defined as any points outside the range:
½median t MAD;medianþ t MAD ð1Þwhere t is a parameter that controls the sensitivity to outliers. The
Hampel method has been shown to identify more outliers than
other methods [31]. This characteristic makes the Hampel method
particularly suited to our application, where it is important that
abnormal results are identified and removed. After outlier identifi-
cation, patients are sorted into two groups – those with no outlier
results at any time, and those with at least one outlier result at
some point in their record. These groups will be referred to as the
non-outlier and outlier populations respectively. The date of the
first outlier result is also retrieved for patients in the outlier group.
2.3. Steps 3–6: The cycle
In step 3, unique ICD9 codes from encounters for each patient,
and their frequency in the outlier population, were found. Only
codes that occurred before the date of the outlier result, or up to
n days afterward, are considered, where n is a parameter than
can be varied. This ensures that the method identifies ICD9 codes
that are relevant to the extreme laboratory results, rather than
detecting treatments for – or complications of – the disease. The
number of unique patients with each ICD9 code is recorded in
the outlier population. The number of unique patients with the
same ICD9 codes in the non-outlier population is also calculated.
Codes from all patient encounters are considered for the non-
outlier population.
Fisher’s Exact Test is used to determine overrepresentation (or
enrichment) of each ICD9 code in the outlier population [32–34].
Bonferroni’s correction for multiple hypothesis testing is applied.
The most overrepresented ICD9 code in the outlier population is
identified in this manner. In step 4, if the associated p-value is
below a, which can be varied as a parameter, the ICD9 code is con-
sidered ‘‘associated” with extreme laboratory results. In step 5, all
patients with a mention of this ICD9 code at any time point are
identified and excluded from all further analysis. In order to be
considered for this removal step, the ICD9 code must also exceed
a predefined frequency in the outlier population, given by the
parameter b. This requirement prevents ICD9 codes for rare dis-
eases that appear once in the outlier population being chosen as
the most significant code, avoiding unnecessary iterations and
speeding up the method.
If there is a tie for the most overrepresented ICD9 code, all tied
ICD9 codes are removed, and an alert will be triggered to inform
the user that this situation has occurred. No ties were encountered
at any point during the development or evaluation of LIMIT, and so
the impact of different approaches to breaking ties were not
investigated.
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ing population, until no ICD9 codes have p-values that satisfy the
significance cutoff. The population remaining at the end of this
process, step 6, is considered to be healthy with respect to the lab-
oratory test of interest, and the test results from that population
are used to define reference intervals for the laboratory test. The
reference interval includes the central 95% of the results – the
lower reference cutoff is the 2.5th percentile, and the upper refer-
ence cutoff is the 97.5th percentile.2.4. Step 7: Validation and testing
Several studies have established reference intervals for classical
chemistry values such as serum potassium and sodium levels, that
are accepted as being suitable for use across institutions
[24,35–37]. Such reference intervals will be referred to as
‘harmonized’ hereafter. Serum sodium test intervals were used in
the development of LIMIT, since harmonized reference intervals
exist for this test. Using these harmonized test results, appropriate
ranges for the parameters (t, n, a, and b) in LIMIT could be defined.
The harmonized intervals used were from the Nordic Reference
Interval Project (NORIP) [35], the AACB ‘Harmonised Reference
Intervals for Adults’ (AHRIA) [24], and the UK Pathology Harmony
project [37]. Sodium test results were extracted from STRIDE, and
the parameters in LIMIT were adjusted to give reference intervals
that match the harmonized reference intervals.
For validation, LIMIT was used to find reference intervals for
serum potassium levels. Harmonized intervals from the same stud-
ies as the sodium intervals were used for comparison with the
results given by LIMIT.
To evaluate the effect of the number of samples on the resulting
reference intervals, serum potassium test results were extracted
from STRIDE, subsets of these results were randomly selected,
and LIMIT was used to produce reference intervals. Subsets con-
sisting of 25%, 50% and 75% of the total available test results were
used. Ten random subsets of each size were produced and tested.
The resulting intervals were compared to one another and to the
intervals produced using the entire potassium data set.
As a test case, LIMIT was used to find reference intervals for
total hemoglobin in whole blood. Hemoglobin was chosen because
it is a high volume test, and reference intervals are known to
depend on patient age and gender [38], allowing the impact of par-
titioning to be investigated. Six patient cohorts were used for this
study, based on the age and gender criteria currently used for
interpretation at Stanford Health Care. These cohorts are defined
in Table 1, which also gives the number of unique patients in each
cohort. Finding hemoglobin test intervals is a more difficult task for
LIMIT, since there is widespread anemia in the hospitalized popu-
lation [2].
A red blood cell specific a posteriori method described by Kullo
et al. was separately applied to produce reference intervals for
hemoglobin test values [21]. Kullo et al. list ICD9 codes that should
be excluded when looking for normal red blood cell data, as well as
the exclusion periods around the mentions of these codes. Kullo’s a
posteriori method and LIMIT were both applied to the same data.
The reference intervals produced by both methods were compared
to the intervals currently used at Stanford Health Care.Table 1
Unique patients in each cohort defined for hemoglobin laboratory testing.
Gender: Female Male
Age (years): 2–6 2–6
# of unique patients with hemoglobin results 2632 3250It is difficult to evaluate sets of reference intervals, since the
ground truth of whether patients needed medical intervention to
treat their condition is not directly available. In a clinical setting,
physicians use professional judgment to determine patient treat-
ment. To try to capture this, prescriptions for iron supplement
were used to indicate that hemoglobin levels were low enough
to be clinically actionably. The ground truth was then defined
using the presence of pharmacy orders for a prescription for iron
supplements up to 3 days after the laboratory test. Performance
metrics for the three sets of hemoglobin reference intervals could
then be calculated.
2.5. Parameter selection
LIMIT requires the selection of four parameter values. The first
parameter, t, determines the sensitivity of outlier detection, as
described in Equation [1]. The second parameter, n, specifies the
number of days after the outlier laboratory result that ICD9 codes
are considered for removal. This time margin ensures that labora-
tory results have been received and considered by the physician,
and any diagnoses made have been added to the patient record.
The parameters a and b define the conditions that must be satisfied
for an ICD9 code to be deemed associated with an abnormal result.
The parameter a declares the p-value cutoff that the ICD9 code
must be below, and b describes the proportion of patients in the
outlier population that must have the ICD9 code. Parameters were
chosen based on the appropriateness of the resulting reference
intervals for sodium.
3. Results
3.1. Harmonized laboratory tests
LIMIT was used to find reference intervals for sodium and
potassium levels in the blood, which have existing harmonized ref-
erence intervals [35–37]. Fig. 2 shows a number of different pub-
lished sets of sodium and potassium reference intervals, as well
as the reference intervals produced using LIMIT. Table 2 shows
the range of parameter values that were tested. LIMIT was found
to be relatively insensitive to parameter perturbations. The full
results of the parameter sensitivity analysis can be seen in Supple-
mentary Fig. 1 while Fig. 2 includes the range of results found in
the parameter sensitivity analysis. The set of parameters chosen
are shown in Table 2, and correspond to the sodium intervals that
best matched the harmonized intervals.
We examined subsets of the potassium data in order to assess
the effect of sample size on the resulting reference intervals. Table 3
shows the intervals produced using three subsets of the data, as
well as the intervals produced using all of the data. The resulting
reference intervals are different when a subset of less than 75% is
used. This corresponds to around 270,000 data points in the data
set, and around 55,000 unique patients.
3.2. Hemoglobin reference intervals
Hemoglobin results were stratified based on age and gender
into subgroups that are currently used to interpret hemoglobin
tests at Stanford Health Care. Table 1 shows these groupings, andFemale Male Female Male
6–12 6–12 >12 >12
2780 3185 184,177 154,447
Reference intervals for serum Sodium levels Reference intervals for serum Potassium levels
Fig. 2. Comparison of reference intervals for sodium (left) and potassium (right). LIMIT was used to find reference intervals using each combination of parameter values (see
Table 2), and the resulting intervals were overlaid at 10% transparency. The reference intervals at the chosen parameters were 132–143 mmol/L for sodium, and 3.3–
5.4 mmol/L for potassium. There was very little variation in the resulting intervals as the parameters of LIMIT were varied.
Table 2
Parameter ranges tested. The parameter t was tested in increments of 1, the
parameter n was tested in increments of 2, the parameter a was tested at the values
[0.01 0.05 0.1] and the parameter b was tested at the values [0.001 0.005 0.01]. All
combinations of these parameters were tested.
t n a b
Range tested 2–4 0–5 0.005–0.2 0.001–0.08
Chosen parameter 3 3 0.05 0.005
Table 3
Range of lower and upper reference intervals produced using LIMIT with subsets of
the serum potassium results.
Proportion of data
used (%)
Upper reference interval
(mmol/L)
Lower reference interval
(mmol/L)
100 3.3 5.4
75 3.2–3.3 5.4
50 3.2 5.3–5.4
25 3.1–3.2
Table 4
Numbers of unique patients remaining in each cohort at step 6 of LIMIT, when
reference intervals are calculated, and the number of unique patients remaining at the
end of Kullo’s a posteriori method. Percentages of the original patient cohorts are also
given, rounded to the nearest percent. LIMIT consistently preserves a higher
proportion of patients.
Gender: Female Male Female Male Female Male
Age (years): 2–6 2–6 6–12 6–12 >12 >12
# of unique patients: 1700 1957 1929 2275 57,112 35,762
– LIMIT (77%) (71%) (81%) (83%) (41%) (30%)
# of unique patients: 144 156 1119 1296 43,987 32,987
– a posteriori method (7%) (6%) (47%) (47%) (31%) (28%)
280 S. Poole et al. / Journal of Biomedical Informatics 59 (2016) 276–284the number of unique patients in each group. Kullo’s previously
published a posteriori method was applied to the same data, for
use as an independent control [21]. The reference intervals found
using LIMIT are compared to the intervals currently used at
Stanford Health Care, and to the intervals found using the a
posteriori approach. The results are shown in Fig. 3. Table 4 shows
the numbers of unique patients remaining in step 6, in the popula-
tions used to calculate the reference intervals.Fig. 3. Comparison of reference intervals for hemoglobin. Both sets of calculated limits (t
currently used intervals, however the LIMIT intervals are consistently narrower than thTo further investigate the efficacy of LIMIT in determining refer-
ence intervals for specific populations, hemoglobin results were
split into two groups depending on whether the test was per-
formed in an inpatient or an outpatient setting, and LIMIT was used
to find the reference interval for each group. The intervals resulting
from this split can be found in Supplementary Fig. 2.
Alternative approaches to excluding abnormal laboratory test
results have focused on removing outliers so that the distribution
of test results has amoreGaussian density [13,18,19]. Such transfor-
mation allows comparison of distributions as well as computation
of reliable summary statistics such as means and standard devia-
tions. Such normal transformationwas accomplished as a side effect
of executing LIMIT, without requiring a numerical transformation.
Fig. 4 shows the result densities before and after LIMIT for hemoglo-
bin test results from the male cohort aged greater than 12 years.hose produced using LIMIT and using Kullo’s a posteriorimethod) are wider than the
e intervals produced using Kullo’s a posteriori method.
Fig. 4. The distribution of results in the original population (yellow) and the
population remaining after LIMIT analysis (red) for hemoglobin test results in the
male cohort aged greater than 12 years old. LIMIT excludes many of the low results,
and the distribution becomes narrower and more Gaussian. No numerical trans-
formation was performed. This change in the distribution was produced as a side-
effect of executing LIMIT. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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The performance metrics for the three sets of hemoglobin refer-
ence intervals were calculated using the presence of a prescription
for iron supplements within 3 days of the laboratory test to indi-
cate clinically actionable low hemoglobin levels. These prescrip-
tions were drawn from STRIDE. Fig. 5 shows the positive
predictive value (PPV) and the specificity plotted against sensitiv-
ity for the three reference intervals, for each cohort.3.4. Over-represented ICD9 codes
LIMIT produces a list of ICD9 codes that are significantly over-
represented in the outlier populations with low, or high, test
results. The 10 most significant ICD9 codes identified by LIMIT
for each analysis are shown in Supplementary Tables 1–8. Many
of the ICD9 codes found to be associated with abnormal hemoglo-
bin levels are clearly related, for example codes for anemia and for
blood transfusion. Significant ICD9 codes also include surgicalReference 
interval set
Fig. 5. (Left) PPV against sensitivity and (right) specificity against sensitivity for all si
calculated reference intervals (triangles), and reference intervals calculated using LIMIT (
than the currently used intervals, at the cost of sensitivity. Performance metrics were
response to the test value.procedures, where blood loss would be expected, as well as chronic
diseases. The ICD9 codes associated with abnormal sodium and
potassium levels include illness indicators such as mechanical ven-
tilation, an intervention often used on surgical and critically ill
patients, who in turn often have significant metabolic imbalances.
Furthermore, mechanical ventilation itself has been shown to
affect metabolic concentrations [40].4. Discussion
We presented a method, LIMIT, to use existing clinical and lab-
oratory data to learn reference intervals of laboratory tests. LIMIT
meets IFCC recommendations, as it inherently specifies the charac-
teristics of the reference population by listing ICD9 codes that
result in exclusion from this population. Essentially, LIMIT takes
the advantages of a posteriori approaches, and removes the need
for expert annotation, making the method much more scalable
and widely usable. Therefore, LIMIT makes it simple to find refer-
ence intervals that are appropriate for any patient population.
The results of this study show that it is possible to use laboratory
results and coded diagnoses to learn laboratory test reference
intervals.
Sodium serum levels were used to choose the parameters of the
method, by using different sets of parameters to generate reference
intervals. These intervals were then compared to sets of harmo-
nized intervals. The intervals produced by LIMIT did not vary
widely during testing of different parameter sets. As validation,
LIMIT was used to find reference intervals for potassium serum
levels, using the chosen parameter values. The resulting intervals
were similar to existing harmonized intervals.
Subsets of potassium serum results were used to study the
effect of sample size on the reference intervals produced by LIMIT.
The results were less accurate when the data set that used as input
to LIMIT contained less than 270,000 samples from around 55,000
unique patients. For good performance, it is recommended that
data sets containing more than 270,000 samples are used as input
to LIMIT. It is also important that the data set contains test results
for a large number of patients, since data points are removed at the
patient level based on what ICD9 codes they have.Patient 
partition
x patient partitions, found using current reference intervals (circles), ’a posteriori’
squares). The intervals found by LIMIT consistently give a higher PPV and specificity
calculated based on the prescription of an iron supplement as a clinical action in
282 S. Poole et al. / Journal of Biomedical Informatics 59 (2016) 276–284Hemoglobin results were used as a way to test the method. The
intervals currently used at Stanford Health Care were used for
comparison, along with the intervals produced by an a posteriori
method. The LIMIT intervals are similar to those produced using
the a posteriorimethod and to the current intervals, and are consis-
tently narrower than the intervals produced using the a posteriori
approach. This finding demonstrates that LIMIT is able to perform
as effectively as a more labor intensive a posteriori method. As
shown in Fig. 4, the hemoglobin test results from the original pop-
ulation are extremely skewed towards the low end, indicating ane-
mia. LIMIT is able to remove the majority of the lower results,
however the reference intervals calculated using the remaining
patients consistently extend below the currently used intervals,
as shown in Fig. 3. This shows that there is wider variation in
‘healthy’ patients in hospital settings than in actual healthy popu-
lations. The reference intervals produced by LIMIT give a higher
positive predictive value for determining whether an iron supple-
ment was prescribed, indicating that these intervals give a closer
approximation to how physicians actually respond to hemoglobin
levels among their hospitalized patients than the currently used
intervals. This higher positive predictive value does come at the
cost of lower sensitivity, as shown in Fig. 5. It is difficult to assess
this reduction in sensitivity, because the iron supplements were
prescribed based on the original ranges, and it is difficult to deter-
mine whether these prescriptions could have been safely avoided.
Further work is required to determine whether the trade off
between sensitivity and positive predictive value is justified.
Kullo et al. give the 25th, 50th and 75th percentiles of the
hemoglobin measurements of their population after the a posteriori
method was applied. Their population had higher hemoglobin
measurements than the population used in this study, as shown
in Table 5. Kullo et al. used data from patients that were recruited
as part of Mayo Clinic’s Electronic Medical Records and Genomics
study, and as is likely to contain healthier individuals than the
STRIDE patient population. It is likely that LIMIT would produce
higher reference intervals if used on a healthier population such
as the Mayo study cohort.
As shown in Table 4, LIMIT preserves a larger proportion of
patients than the a posteriori method while giving narrower inter-
vals, demonstrating that a more specific group of patients are
removed by LIMIT than by using the a posteriori method.
By comparing the distribution of the results from the entire
population to the distribution of the results remaining at the end
of the analysis (see Fig. 4), we see that LIMIT automatically moves
the results towards a normal distribution. Several existing methods
exclusively use statistical methods for identification of abnormal
laboratory test results [13,18,19,41]. It is reassuring that LIMIT
automatically moves the distribution of results towards Gaussian,
as this is the aim of other studies.
Prescriptions for iron supplement were used to calculate perfor-
mance metrics of the hemoglobin reference intervals. Reference
intervals found using LIMIT had a higher PPV and specificity than
the existing reference intervals for all of the six age and gender
based groups, at the cost of sensitivity. It is possible that other
actions were taken to correct low hemoglobin levels, which wereTable 5
Percentiles of hemoglobin test results in population remaining after a posteriori
exclusion criteria have been applied, for the original study [21] and for our study.
25th
percentile
(g/dL)
50th
percentile
(g/dL)
75th
percentile
(g/dL)
Mayo Clinic dataset (Kullo et al.
study [21])
13.3 14.1 15.0
STRIDE dataset (our study) 10.6 12.7 14.4not captured in this analysis. Therefore, the evaluation of the per-
formance characteristics is a comparison between the sets of inter-
vals, and should not be interpreted as the ‘‘true” PPV, sensitivity or
specificity of the laboratory test.
Previous studies that have used laboratory data to find hemo-
globin reference intervals produced intervals that were consider-
ably higher than those found using LIMIT [42,43]. The data used
in these studies were gathered from patients outside normal clinic
visits, meaning that the patients did not have any specific health
concerns that were being addressed by testing their hemoglobin
levels [42,43]. In contrast, all of the data in the STRIDE database
that were used in our study is from current patients, whether in
an inpatient or an outpatient setting. The different contexts in
which the laboratory tests were performed could explain the dif-
ference in the reference intervals found in our study and in these
previous studies [44].
The inclusion of inpatient hemoglobin levels in our study could
also have contributed to the lower reference intervals. Including
additional features in the analysis, for example medications, proce-
dures or results from different laboratory tests, could improve the
performance of LIMIT. Overall, intervals calculated from outpatient
test results were higher than those calculated from inpatient test
results, as would be expected (Supplementary Fig. 2). Outpatient
testing intervals were very similar to those found using all testing
results. Inpatient testing intervals were very wide, which could
have been due to a lower proportion of healthy patients in an inpa-
tient setting, or to large amounts of variation in the inpatient
population.
An advantage of the LIMIT is the ability to identify reference
intervals for highly specific patient cohorts. The context in which
a laboratory test is ordered has been shown to be an important
consideration when interpreting the results [4,44]. Because LIMIT
is automated, reference intervals can be established quickly and
inexpensively, allowing separate reference intervals to be calcu-
lated for tests with different ordering reasons. The automated nat-
ure of LIMIT also allows comorbidities to be taken into account, by
using data from a population of patients with the same comorbidi-
ties as the patient of interest.
Reference intervals could also be established for protein synthe-
sis and gene expression levels as these tests become widely used.
Large amounts of data will be required, which could be obtained
from publically available data sets such as the Gene Expression
Omnibus, the Expression Atlas, the Multi Omics Profiling
Expression Database (MOPED), and the Human Protein Atlas.
LIMIT can also be used to verify existing reference intervals
across institutions. In addition, calculation of intervals using data
from institutions that use different measurement instruments will
allow the variation between these instruments to be quantified.
Doing so will allow institutes to implement reference intervals that
are specifically established for their patient population and mea-
surement system. The automated nature of LIMIT means that insti-
tutions are able to recalculate reference intervals on a regular
basis.
4.1. Limitations
LIMIT removes one ICD9 code at a time. In this analysis, ICD9
codes were not collapsed to their base three digits. Because of this,
disorders that are split into multiple ICD9 codes will have fewer
patients, and hence less statistical significance; therefore, LIMIT
may not remove them, or may remove only one or two of the sub-
categories. A similar effect could occur if there are variations in
coding practices within an institution, since a single diagnosis
may be represented as several different ICD9 codes (which could
get worse with usage of ICD-10). This is a limitation of LIMIT,
which could be addressed if ICD9 codes were grouped, for example
S. Poole et al. / Journal of Biomedical Informatics 59 (2016) 276–284 283by using information theoretic approaches [45], into disease cate-
gories which have the same level of specificity.
A strength of LIMIT is its ability to produce instrument-specific
reference intervals, however data detailing the instrument and/or
technique used in analysis is not currently available in the clinical
data warehouse used in this study. This information is stored in
Laboratory Information Management Systems (LIMS), and could
be integrated with the clinical data warehouse in the future. Incor-
porating this information would entail a significant amount of data
integration effort because the LIMS are typically separate from the
electronic medical record systems, from which data flows to the
clinical data warehouse.
LIMIT was developed under the assumption that a significant
proportion of specimens that are sent for testing are clinically nor-
mal. A focus of current study is the identification and reduction of
unnecessary lab tests [46–50]. A reduction in unnecessary tests
would likely cause the proportion of clinically normal specimens
being tested to decrease, impacting the performance of LIMIT. This
issue can be overcome by accessing larger patient cohorts, for
example combining data sets from several institutions, to increase
the number of normal specimens and results in the data set. For
the one test where we examined the minimum sample size
requirement, reference intervals could be learned using data from
about 55,000 individuals. Even if testing rates fall, by combining
data from several institutions, the necessary sample size can be
assembled. Using data from multiple institutions increases vari-
ance due to difference in testing procedures, however the larger
sample sizes could decrease the variance of LIMIT. We note that
the overall result of such data pooling has not yet been evaluated.5. Conclusion
We present LIMIT, an unsupervised learning method to extract
reference intervals from the electronic medical record. LIMIT com-
plies with IFCC recommendations, in that the characteristics of the
population used to define the reference intervals are well
described. Results show that LIMIT produces usable reference
intervals for sodium, potassium and hemoglobin laboratory results.
The results of this study show that it is possible to use laboratory
results and coded diagnoses from the EHR to learn laboratory test
reference intervals.
LIMIT represents a fast and inexpensive solution for calculating
reference intervals, which can allow a personalized interpretation
of laboratory results, by calculating a reference interval from a
cohort of similar patients. Hemoglobin results stratified according
to age, gender, and inpatient/outpatient status demonstrate the
capacity of LIMIT to find reference intervals for highly specific
cohorts.
LIMIT generates lists of ICD9 codes that are significantly related
to extreme laboratory test results. Further analysis of these codes
that are significantly associated with extreme values of unrelated
laboratory tests could identify existing diagnostic tests whose
results may be markers for specific disease states.Conflict of interest
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